RPL22L1 and hepatocellular carcinoma: Inhibitors of MEK (U0126, MEKi) and ERK (SCH772984 and Ulixertinib, ERKi) were used to interrogate whether RPL22L1 affected malignant functions of HCC cells by activating MEK-ERK.